Ron Lancaster has led early stage incubation and large scale global R&D teams in Medical products R&D for 24 years. He has provided consulting services on innovation, incubation, product development, risk management, technology assessments and due diligence to entrepreneurs, analysts, and corporate investors. Prior to his current role as Director of Corporate Research at Boston Scientific, he spent 11 years with Stryker in multiple Divisions including VP/Division Leader, Stryker Development, 10 years with J&J at 2 Divisions, and 2 years leading contract R&D. He has been a professional consultant for Gerson Lehrman, Global Guidepoint, RTI Biologics, and Ximedica. Ron is an advisor to Pediaworks, a non-profit organization fostering innovation for pediatric care, has served as Vice Chairman of the Board of CIBOR technologies, and has been an industry advisor to the University of Missouri Biodesign Program. Ron, and his teams, enjoy a legacy of delivering high value innovations that continue to drive growth for those Corporations by enabling Health Care Professionals and improving patient’s lives. During his tenure, he has incubated and developed technologies in protein formulation and carriers, regenerative medicine, absorbable and non-absorbable musculoskeletal fixation, neurostimulation, obesity devices, biomaterials, surgical navigation, minimally invasive tissue staplers/sealers, cardiac introducers and arterial closures, hydrocephalus valves and shunts, Women’s health, and external bracing and supports. After serving tours in the USAF, Ron completed his BSME and Biomedical Engineering Certification followed by an MS in Biomechanics at the Michigan State University Colleges of Engineering and Osteopathic Medicine, respectively. Throughout his tenure, Ron has developed many tools that enable successful navigation around the barriers to innovation inherent within large corporate, small private, and start-up cultures.